QuidelOrtho is exploring the sale of its donor screening business, a move that aligns with its efforts to streamline operations and improve its financial standing. This potential divestiture comes as private equity firms increasingly show interest in healthcare companies, particularly those with stable revenue streams like diagnostic testing units. The donor screening business, which saw its revenue fall 40% to $7.8 million in Q1 2026, is being shut down as part of QuidelOrtho's consolidation efforts, signaling a strategic shift away from this segment.
This decision is part of QuidelOrtho's broader strategy to enhance its financial flexibility and focus on higher-growth areas. The company faces significant debt, reported at approximately $2.87 billion, which is substantial compared to its equity-market value of about $826 million. The incoming CFO is expected to prioritize capital allocation and cash-flow improvement, with investors looking for clearer debt-reduction schedules and tighter spending controls.
QuidelOrtho's efforts to optimize its portfolio also include cost-cutting measures, such as eliminating close to 1,000 positions and consolidating its footprint by closing facilities. The company aims to offset headwinds from a weak respiratory season and business disruptions through internal improvements and growth in its point-of-care molecular diagnostics business, particularly with the acquisition and ramp-up of Lex Diagnostics and its Velo system.
The potential sale of the donor screening unit could generate much-needed capital to reduce debt and invest in core businesses with higher margins, such as molecular diagnostics. This strategic move could help QuidelOrtho navigate its financial challenges and position itself for more sustainable long-term growth, despite recent disappointing Q1 2026 earnings where revenue declined 11% year-over-year to $619.8 million, missing analyst estimates of $659.2 million.
